Evidence map›Paper›PMID 40335653›Full record

Trial reportScientific reports2025

Prospective uncontrolled clinical study shows rapid and long lasting relief of heartburn and acid related gastric discomfort with Refluthin.

Ahmed Madisch, Fabio Pace, Daniel Menzel, Petra Funk, Berenike Stracke, Christiane Schön, Joachim Labenz

Abstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ahmed MadischGastroenterology Center Bethanien, Im Prüfling 21-25, 60389, Frankfurt am Main, Germany. Ahmed.Madisch@diakovere.de.ORCID http://orcid.org/0000-0001-9163-5893
Fabio PaceGI Unit, Bolognini Hospital, Via Paderno 21, 24068, Seriate, Bergamo, Italy.
Daniel MenzelNutritional CRO, BioTeSys GmbH, Schelztorstrasse 54-56, 73728, Esslingen, Germany.
Petra FunkResearch and Development, Dr. Willmar Schwabe GmbH & Co. KG, Willmar-Schwabe-Straße 4, 76227, Karlsruhe, Germany.
Berenike StrackeGlobal Medical Affairs, Dr. Willmar Schwabe GmbH & Co. KG, Willmar-Schwabe-Straße 4, 76227, Karlsruhe, Germany.
Christiane SchönNutritional CRO, BioTeSys GmbH, Schelztorstrasse 54-56, 73728, Esslingen, Germany.
Joachim LabenzMedical Center, Flughafenstraße 2/2a, 57299, Burbach, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heartburn and acid regurgitation are main symptoms of gastro-esophageal reflux, a widespread complaint with a significant impact on quality of life (QoL). Refluthin® for Heartburn chewable tablets (Refluthin) are a symptomatic treatment option containing a combination of an antacid (CaCO

Indexed as

AntacidsCalcium CarbonateGastroesophageal RefluxHeartburnAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeTreatment OutcomeAntacidsCalcium CarbonateAcid regurgitationGastro-esophageal refluxHeartburnOpuntia ficus-indica extractRefluthinSymptom relief

Identifiers

PMID40335653
PMCPMC12059117

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.